<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>英矽智能 &#8211; 投黑马</title>
	<atom:link href="https://touheima.com/tag/%E8%8B%B1%E7%9F%BD%E6%99%BA%E8%83%BD/feed/" rel="self" type="application/rss+xml" />
	<link>https://touheima.com</link>
	<description>AI 时代的左侧研究机构</description>
	<lastBuildDate>Wed, 29 Jul 2026 03:10:51 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://touheima.com/wp-content/uploads/2023/12/Touheima-icon-1-150x150.png</url>
	<title>英矽智能 &#8211; 投黑马</title>
	<link>https://touheima.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>AI科学发现进入验证期：资本为何开始重估实验闭环？【黑马雷达 第015期】</title>
		<link>https://touheima.com/radar-20260729-ai-science-validation-loop/</link>
		
		<dc:creator><![CDATA[投黑马]]></dc:creator>
		<pubDate>Wed, 29 Jul 2026 03:10:48 +0000</pubDate>
				<category><![CDATA[黑马雷达]]></category>
		<category><![CDATA[Chai Discovery]]></category>
		<category><![CDATA[CuspAI]]></category>
		<category><![CDATA[MindRank]]></category>
		<category><![CDATA[一级市场]]></category>
		<category><![CDATA[新材料]]></category>
		<category><![CDATA[早期投资]]></category>
		<category><![CDATA[晶泰科技]]></category>
		<category><![CDATA[生物科技]]></category>
		<category><![CDATA[英矽智能]]></category>
		<guid isPermaLink="false">https://touheima.com/?p=2422</guid>

					<description><![CDATA[<p>AI科学发现正在跨过一道关键分界线：会生成候选答案已经不够，能用真实实验淘汰错误、沉淀数据并兑现临床或产业价值，才有资格获得下一轮定价。本期拆解五类代表性玩家、四个早期机会与三组验证信号。</p>
]]></description>
										<content:encoded><![CDATA[<p>AI科学发现正在跨过一道关键分界线：会生成候选答案已经不够，能用真实实验淘汰错误、沉淀数据并兑现临床或产业价值，才有资格获得下一轮定价。本期拆解五类代表性玩家、四个早期机会与三组验证信号。</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
